

PRESS RELEASE

Study: Periodontitis Increases Risks in Case of Coronavirus / Covid-19

Argument for natural prophylaxis using neither antibiotics nor antiseptics

Hennigsdorf b. Berlin, 15 March 2021 – Inflammation of the gums – referred to as periodontitis or periodontal disease – may negatively affect on and aggravate the course of Covid-19 infections (Coronavirus infections). This said Professor Dr Christine Lang, professor for microbiology at Technical University Berlin and member of BELANO medical AG's board of directors, in an article published on the blog www.gesunde-bakterien.de.

She references a study conducted by international researchers (Journal of Clinical Periodontology 2021, <https://doi.org/10.1111/jcpe.13435>) who found that compared to patients without periodontitis, patients with periodontitis were on average 3.5 times more likely to be admitted to an ICU and 4.5 times more likely to need assisted ventilation. "In addition, Covid-19 patients with periodontitis were almost nine times more likely to die, compared to those without periodontal disease", Professor Dr Lang says in her article.

The study supposes that one possible reason may be that the bacteria which cause periodontitis are inhaled from the mouth and can lead to further infections in the lung. To reduce this risk, it may be appropriate to treat Covid-19 patients suffering from periodontal disease with oral antiseptics prior to assisted ventilation, according to researchers involved in the study.

Here, Professor Lang advocates probiotic prophylaxis based on good (commensal) bacteria in order to fundamentally reduce the number of pathogens, and thus the overall risk of periodontal disease. Studies have shown that worldwide, at least one in two adults suffers from periodontal disease at some time during their lives. In addition to loss of teeth and a more severe course of Covid-19 / Corona infections, the inflammation may also promote Alzheimer's disease and cancer, Lang writes further.

About BELANO medical AG:

BELANO medical AG is a biotechnology company which leverages the findings of its research into beneficial microorganisms for pharmaceutical and care products. The company develops and brings to market novel approaches to medical skin care, disease prevention, and the support of healing processes. In this way, new therapeutic options are created for diseases and indications which currently cannot be treated satisfactorily. BELANO's mission is to make its patented agents and products available to everyone. To do so, the company relies on national and international collaboration with distributors and larger partners.

For further Information:

BELANO medical AG

Neuendorfstraße 19

D-16761 Hennigsdorf (Berlin), Germany

Phone: +49 (0)3302 86 37 995

info@belanomedical.com

www.belanomedical.com